Could a bone drug fix a rare blood disorder?
NCT ID NCT07471516
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether zoledronic acid, a drug usually used for bone health, can help people with a rare inherited anemia called congenital dyserythropoietic anemia (CDA). Only 2 adults with CDA who have low hemoglobin or need regular transfusions will receive 4 doses of the drug. Researchers will check if it raises hemoglobin levels and reduces transfusion needs over 12 to 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zoledronic acid
- What this could lead to
- If it works, this could point toward a new treatment option for people with congenital dyserythropoietic anemia, potentially reducing their need for blood transfusions.
- What could go wrong
- This is a very early, tiny study with only 2 participants, so results may not apply to others. Zoledronic acid can cause kidney problems and low calcium, and it's unclear if it will improve anemia at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL DYSERYTHROPOIETIC ANEMIA (CDA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.